Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Introduction: Chimeric antigen receptor (CAR) T cells have recently become an important ... trials for CAR T cells in autoimmune disease are focused on anti-CD19 and anti-BCMA CAR T cells. We believe ...

Background: T-cell receptor (TCR) repertoires provide insights into tumor immunology, yet their variations across digestive system cancers are not well understood. Characterizing TCR differences ...

The Research Center for Computer-Aided Drug Discovery, The Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China University of Chinese Academy of Sciences, ...

For treating brain diseases, the bispecific antibodies from Grabody contain a domain designed to bind to insulin-like growth factor 1 receptor (IGF1R), a receptor that transports proteins across ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of haematological malignancies and has demonstrated efficacy in early trials for solid tumours, neurological and ...